Scribe Therapeutics

Scribe Therapeutics is a molecular engineering company focused on developing next-generation CRISPR-based genetic medicines for the treatment of a wide range of diseases. Founded by CRISPR pioneers and leading molecular engineers, including Jennifer Doudna, Scribe utilizes a proprietary, fully integrated platform called CRISPR by Design™ to engineer custom-designed CRISPR enzymes and delivery technologies that exhibit superior activity, specificity, and deliverability compared to existing CRISPR technologies. This allows them to develop safer and more effective in vivo therapies for diseases like neurodegeneration, ophthalmic diseases, and genomic disorders.

Scribe's innovative approach has attracted significant attention and investment from leading life sciences investors, including Andreessen Horowitz, Avoro Ventures, and OrbiMed Advisors. They have formed several strategic collaborations with major pharmaceutical companies like Biogen, Sanofi, and Eli Lilly, leveraging their expertise and resources to accelerate the development and commercialization of their CRISPR-based therapeutics. Through their continued research and development, Scribe aims to redefine the landscape of genetic medicine and provide lasting treatment options for patients suffering from a variety of complex diseases.

Scribe Therapeutics is a molecular engineering company dedicated to revolutionizing the development of CRISPR-based genetic medicines. The company's mission is to create optimized in vivo therapies that permanently treat the underlying causes of disease, with a particular focus on addressing diseases with high unmet needs, such as neurodegenerative disorders. Their innovative CRISPR by Design™ approach involves engineering bacterial immune systems into a suite of highly specific and effective genome editing tools, overcoming the limitations of current CRISPR technology. By building best-in-class in vivo therapeutics, Scribe aims to transform the standard of care for millions of patients suffering from genetic conditions.

Scribe Therapeutics fosters a culture built on four core values: integrity, creativity, drive, and pragmatism. They emphasize a collaborative environment where team members are encouraged to push boundaries and innovate, driven by a shared mission to deliver on the promise of CRISPR technology and create a real impact for patients and families. This culture reflects their commitment to rapid innovation and a pragmatic approach to bringing their engineered CRISPR tools to the clinic.